Fused imidazole and triazole derivatives as 5-htl receptor agonists

Abstract From the Canadian patent

Compounds of formula (I) wherein Q represents the residue of a six-membered aromatic or heteroaromatic nucleus containing zero one or two nitrogen atoms; V represents nitrogen or C-A2; E represents a bond or a straight or branched alkylene chain containing from 1 to 4 carbon atoms; F represents a group of formula (a); U represents nitrogen or C-R2; B represents oxygen sulphur or, N-R3; R1 represents -CH2.CHR4.NR6R7 or a group of formula (i), (ii), (iii) or (iv); are selective agonists of 5-HT1-like receptors and are therefore useful in the treatment of clinical conditions, in particular migraine and associated disorders for which a selective agonist of these receptors is indicated.